Variable Bcl-2 phenotype in benign and malignant lesions of urothelium

Cancer Letters

Volumn 128, Issue 1, 1998, Pages 87-92

  Bilim, Vladimir N ^a   Tomita, Yoshihiko ^a   Kawasaki, Takashi ^a   Takeda, Masayuki ^a   Takahashi, Kota ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bax; Bcl 2; p53; Transitional cell cancer

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR;

ADULT; AGED; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROGENITAL NEOPLASMS; UROTHELIUM;

EID: 0032486221     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00055-X     Document Type: Article

References (28)

1. Apte S., Mattei M., Olsen B. Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAX delta. Genomics. 26:1995;592-594.
2. Bhargava V., Kell D., van-de-Rijn M., Warnke R. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am. J. Pathol. 145:1994;535-540.
3. Bilim V., Tomita Y., Kawasaki T., Katagiri A., Imai T., Takeda M., Takahashi K. Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer. J. Natl. Cancer Inst. 88:1996;686-688.
4. Branet F., Brousset P., Krajewski S., Schlaifer D., Selves J., Reed J., Caron P. Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. J. Clin. Endocrinol. Metab. 81:1996;2726-2730.
5. Campos L., Rouault J., Sabido O., Oriol P., Roubi N., Vasselon C., Archimbaud E., Magaud J., Guyotat D. High expression of bcl-2 in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:1993;3091-3096.
6. Clarke A., Purdie C., Harrison D., Morris R., Bird C., Hooper M., Wyllie A. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362:1933;849-852.
7. Fairbairn L., Cowling G., Reipert B., Dexter T. Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors. Cell. 74:1993;823-832.
8. Furihata M., Sonobe H., Ohtsuki Y., Yamashita M., Morioka M., Yamamoto A., Terao N., Kuwahara M., Fujisaki N. Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. J. Pathol. 178:1996;133-139.
9. Haldar S., Negrini M., Monne M., Sabbioni S., Croce C. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54:1994;2095-2097.
10. Hollstein M., Sidransky D., Vogelstein B., Harrisp C. p53 mutations in human cancers. Science. 253:1991;49-53.
11. Iggo R., Gatter K., Bartek J., Lane D., Harris A. Increased expressions of mutant forms of p53 oncogene in primary lung cancer. Lancet. 335:1990;675-679.
12. Kawasaki T., Tomita Y., Watanabe R., Tanikawa T., Kumanishi T., Sato S. mRNA and protein expression of p53 mutations in human bladder cancer cell lines. Cancer Lett. 82:1994;113-121.
13. Krajewska M., Krajewski S., Epstein J., Shabaik A., Sauvageot J., Song K., Kitada S., Reed J.C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 148:1996;1567-1576.
14. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V., Niskanen E., Nordling S., Reed J. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55:1995;4471-4478.
15. LeBrun D., Warnke R., Cleary M. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am. J. Pathol. 142:1993;743-753.
16. Lowe S., Schmitt E., Smith S., Osborne B., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
17. Lu Q., Poulsom R., Wong L., Hanby A. Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J. Pathol. 169:1993;431-437.
18. McDonnell T., Troncoso P., Brisbay S., Logothetis C., Chung L., Hsieh J., Tu S., Campbell M. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:1992;6940-6944.
19. Miyashita T., Harigai M., Hanada M., Reed J. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54:1994;3131-3135.
20. Miyashita T., Krajewski S., Krajewska M., Wang H. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
21. Monaghan P., Robertson D., Amos T., Dyer M., Mason D., Greaves M. Ultrastructural localization of bcl-2 protein. J. Histochem. Cytochem. 40:1992;1819-1825.
22. Oltvai Z., Milliman C., Korsmeyer S. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
23. Shiina H., Igawa M., Urakami S., Honda S., Shirakawa H., Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J. Clin. Pathol. 49:1996;395-399.
24. Tomita Y., Bilim V., Kawasaki T., Takahashi K., Okan I., Magnusson K., Wiman K. Frequent expression of Bcl-2 in renal cell carcinomas carrying wild-type p53. Int. J. Cancer. 66:1996;322-325.
25. Tomita Y., Nishiyama T., Watanabe H., Fujiwara M., Sato S. Expression of intercellular adhesion molecule-1 (ICAM-1) on renal-cell cancer: possible significance in host immune responses. Int. J. Cancer. 46:1990;1001-1006.
26. Watanabe R., Tomita Y., Nishiyama T., Tanikawa T., Sato S. Correlation of p53 protein expression in human urothelial transitional cell cancers with malignant potential and patient survival. Int. J. Urol. 1:1994;43-48.
27. Xiong Y., Hannon G., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
28. Yin X., Oltvai Z., Korsmeyer S. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature. 369:1994;321-323.